Developer docs
API playgroundTry for free, no card

Search company profiles

WuXi AppTec, Laboratory Testing Division

Full company profile

uuid004r74k

Namestring
WuXi AppTec, Laboratory Testing Division
Legal namestring
WuXi AppTec
Company typeenum
Public
Founded yearstring
-
Descriptiontext

WuXi AppTec's Laboratory Testing Division is a global contract research organization (CRO) providing preclinical drug development testing services to pharmaceutical and biotechnology companies. The division operates million-square-foot GLP and 21 CFR Part 11-validated laboratory facilities across the United States (Cranbury, New Jersey) and China (Shanghai, Nanjing, Suzhou), with capabilities supporting regulatory submissions to the FDA, EMA, and NMPA. The division's customer base spans large pharmaceutical companies and biotechnology developers advancing small molecules, biologics, and emerging therapeutic modalities through IND and NDA pathways.

The division delivers services across three core testing pillars: Bioanalytical Services (with 70+ UPLC-MS/MS instruments globally, 500+ specialized staff, and 37+ million samples analyzed annually), DMPK Services (including radiolabeled ADME studies with 3H and 14C, metabolite profiling, and in vivo PK), and Safety Assessment Services (general toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology, and carcinogenicity testing). The platform is structured around modality-specific solutions covering small molecules, large molecules, and new modalities including PROTACs, oligonucleotides, ADCs, peptides, CAR-T, and mRNA therapeutics. The division has supported over 1,200 successful IND submissions, conducting 10,000+ in vitro and 5,000+ in vivo studies per year through 300+ validated bioanalytical methods.

The business operates on a fee-for-service contract testing model with quote-based pricing for integrated IND-enabling and NDA-enabling packages, as well as a la carte assay services on multi-year contracts. Distribution is enterprise-direct via field sales teams and dedicated project managers engaged with pharmaceutical and biotech sponsors. The division holds first-mover regulatory positions in China, including the first CMC platform to pass FDA inspection for new chemical entities, the first GLP preclinical laboratory double-certified with OECD and NMPA, and the first GLP/GCP bioanalytical laboratory passing FDA, OECD, and NMPA inspections. As a business unit of WuXi AppTec (publicly traded on the Shanghai Stock Exchange, ticker 603259), the Laboratory Testing Division benefits from the parent group's scale and corporate infrastructure but does not have separately disclosed revenue or financials.

Short descriptiontext

WuXi AppTec's Laboratory Testing Division is a global CRO providing preclinical drug development testing services—including bioanalytical, DMPK, and safety assessment—to pharmaceutical and biotechnology companies across the US, Europe, and China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical testing services, bioanalytical services, drug metabolism pharmacokinetics, safety assessment services, IND-enabling studies
Industry5 codes
PRIMARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAK
Bioanalytical & Biomarker Assays (Preclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAC
Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Preclinical Drug Development Testing Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Preclinical Testing Services
TypeProfessional Services
Description

Fee-for-service preclinical testing contracts covering DMPK, bioanalysis, safety assessment, and regulatory support for drug development programs. Services offered as integrated IND/NDA packages or individual assays

labtesting.wuxiapptec.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Custom IND-Enabling and NDA-Enabling Packages
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing for integrated preclinical testing packages. A la carte assay services also available. No public pricing listed.

labtesting.wuxiapptec.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Contract preclinical drug development testing services for pharmaceutical and biotechnology companies, covering three integrated pillars: Bioanalytical Services (small and large molecule quantification using LC-MS/MS and immunoassays), DMPK Services (in vitro ADME, in vivo PK, metabolite profiling, radiolabeled ADME), and Safety Assessment Services (general toxicology, safety pharmacology, genetic toxicology, DART, carcinogenicity). Services span the full preclinical continuum from discovery through IND and NDA submissions to FDA, EMA, and NMPA across small molecules, biologics, and emerging therapeutic modalities including PROTACs, oligonucleotides, ADCs, peptides, CAR-T, and mRNA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1,200+ successful IND submissions completed
+3 more records
Product overview1 text field

WuXi AppTec Laboratory Testing Division offers a comprehensive, fully integrated preclinical drug development platform encompassing three core service pillars: Bioanalytical Services, DMPK Services, and Safety Assessment Services. These are delivered across multiple therapeutic modality categories (Small Molecule, Large Molecule, and New Modalities including Oligonucleotides, ADCs, Peptides, Protein Degraders/PROTACs, CAR-T, and mRNA). The platform provides end-to-end capabilities from discovery through IND and NDA submission, with global operations in the U.S. and China. Services are delivered through dedicated solutions for IND-Enabling and NDA-Enabling programs, supported by advanced technology platforms including LC-MS/MS, immunoassays, and high-throughput screening systems.

Product and service15 records
1Preclinical Drug Development Services
CategoryPreclinical Drug Development
Description

Comprehensive preclinical drug development testing services encompassing bioanalytical, DMPK, and toxicology testing to support drug candidates from early discovery through IND and NDA submission for pharmaceutical and biotechnology companies.

2IND-Enabling Services
CategoryPreclinical Drug Development
Description

Preclinical studies and regulatory submission support designed to prepare drug candidates for Investigational New Drug (IND) applications to FDA, NMPA, and EMA.

3NDA-Enabling Services
CategoryPreclinical Drug Development
Description

GLP safety assessment and bioanalytical testing services to support New Drug Application (NDA) submissions through Phase I, II, and III clinical trials for pharmaceutical sponsors.

4Small Molecule Solutions
CategoryModality-Specific Solutions
Description

Integrated preclinical testing platform for small molecule therapeutics covering DMPK/ADME, bioanalysis, safety assessment, pharmacology, and CMC from discovery through NDA submission.

5Large Molecule Solutions
CategoryModality-Specific Solutions
Description

Preclinical development services for biologics and biotherapies including bioanalytical, DMPK, safety assessment, pharmacology, and CMC capabilities.

6New Modalities Solutions
CategoryModality-Specific Solutions
Description

Preclinical testing services for emerging therapeutic modalities including PROTACs, oligonucleotides, ADCs, peptides, CAR-T, and mRNA therapeutics.

7Oligonucleotide Solutions
CategoryModality-Specific Solutions
Description

Comprehensive testing services for oligonucleotide therapeutics covering in vitro stability, in vivo pharmacokinetics, advanced bioanalysis, and specialized safety assessments for ASOs, siRNAs, and mRNA oligonucleotides.

8Antibody-Drug Conjugate (ADC) Solutions
CategoryModality-Specific Solutions
Description

End-to-end preclinical testing services for antibody-drug conjugates including linker stability, payload release kinetics, tissue distribution, and specialized bioanalysis for total antibody, intact ADC, and DAR analysis.

9Peptide Solutions
CategoryModality-Specific Solutions
Description

Preclinical testing services for peptide therapeutics including stability assessment, permeability evaluation, tissue distribution, and specialized immunogenicity monitoring for peptides 500-5,000 Da.

10Protein Degrader Solutions (PROTAC)
CategoryModality-Specific Solutions
Description

Specialized testing for targeted protein degraders including PROTACs, molecular glues, and lysosome-directed approaches with capabilities for physicochemical characterization, metabolic profiling, and off-target degradation screening.

11CAR-T Solutions
CategoryModality-Specific Solutions
Description

Preclinical testing services for chimeric antigen receptor T-cell therapies including bioanalysis, biomarker analysis, in vitro and in vivo assays, and immunophenotyping for hematologic malignancies.

12mRNA Solutions
CategoryModality-Specific Solutions
Description

Preclinical testing services for mRNA therapeutics and vaccines including biodistribution studies tracking mRNA and translated proteins, delivery system characterization, and tissue-specific translation assessment.

13Bioanalytical Services
CategoryCore Testing Services
Description

Comprehensive bioanalysis platform supporting small and large molecule programs through discovery, preclinical, and clinical phases with LC-MS/MS, immunoassays, and biomarker validation.

14DMPK Services
CategoryCore Testing Services
Description

Drug metabolism and pharmacokinetic services including in vitro ADME, in vivo PK studies, metabolite profiling, and radiolabeled ADME studies spanning discovery through clinical phases.

15Safety Assessment Services
CategoryCore Testing Services
Description

Comprehensive safety assessment services including general toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology (DART), and carcinogenicity testing across multiple species.

Scale indicator17 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global testing services group with significant pharma clinical and preclinical testing, bioanalytical, and DMPK offerings through Eurofins Discovery and Pharma Services; comparable on testing services model and customer overlap.

TypeBroad incumbent
Description

Global CRO with preclinical laboratory services (post-PRA and early-development services acquisitions) serving pharma/biotech sponsors; overlapping in bioanalytical and central lab services with broader clinical focus.

TypeDirect peer
Description

Preclinical CRO specializing in safety assessment, DMPK, bioanalysis, and research models for pharma/biotech; comparable on GLP toxicology and bioanalytical service lines.

TypeBroad incumbent
Description

Diversified life sciences services giant with preclinical and bioanalytical capabilities embedded in its broader R&D Solutions and laboratory services; comparable on bioanalysis/DMPK but broader in clinical and data offerings.

TypeDirect peer
Description

U.S./China-based CRO providing bioanalytical, DMPK, CMC, and preclinical services to pharma/biotech; directly comparable on integrated IND-enabling preclinical offerings and bilateral U.S.–China footprint.

TypeDirect peer
Description

Post-spin preclinical and clinical CRO offering DMPK, bioanalytical, safety assessment, and central laboratory services to pharma/biotech sponsors; directly comparable in service portfolio and customer base.

TypeDirect peer
Description

Global CRO with a large preclinical Safety Assessment and DMPK/Bioanalysis business serving pharmaceutical and biotech clients across small molecules and biologics; directly comparable in core service lines (GLP toxicology, bioanalysis, DMPK) and end customers.

TypeDirect peer
Description

China-headquartered CRO/CDMO offering integrated preclinical drug discovery, DMPK, bioanalytical and safety assessment services to global pharma/biotech sponsors; directly comparable in service mix, China-based scale, and customer base.

TypeRegional player
Description

China-headquartered clinical CRO with growing preclinical/biologics services targeting China and global pharma; adjacent comparable as a Chinese peer serving similar pharma/biotech sponsors with expanding preclinical capabilities.

TypeDirect peer
Description

Global CRO providing preclinical and clinical bioanalytical, DMPK, and central laboratory services to pharmaceutical and biotech clients; directly comparable in GLP bioanalytical and central lab offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

WuXi AppTec, Laboratory Testing Division

Preclinical Drug Development Testing Serviceslabtesting.wuxiapptec.com

WuXi AppTec's Laboratory Testing Division is a global CRO providing preclinical drug development testing services—including bioanalytical, DMPK, and safety assessment—to pharmaceutical and biotechnology companies across the US, Europe, and China.

What WuXi AppTec, Laboratory Testing Division does

WuXi AppTec's Laboratory Testing Division is a global contract research organization (CRO) providing preclinical drug development testing services to pharmaceutical and biotechnology companies. The division operates million-square-foot GLP and 21 CFR Part 11-validated laboratory facilities across the United States (Cranbury, New Jersey) and China (Shanghai, Nanjing, Suzhou), with capabilities supporting regulatory submissions to the FDA, EMA, and NMPA. The division's customer base spans large pharmaceutical companies and biotechnology developers advancing small molecules, biologics, and emerging therapeutic modalities through IND and NDA pathways.

The division delivers services across three core testing pillars: Bioanalytical Services (with 70+ UPLC-MS/MS instruments globally, 500+ specialized staff, and 37+ million samples analyzed annually), DMPK Services (including radiolabeled ADME studies with 3H and 14C, metabolite profiling, and in vivo PK), and Safety Assessment Services (general toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology, and carcinogenicity testing). The platform is structured around modality-specific solutions covering small molecules, large molecules, and new modalities including PROTACs, oligonucleotides, ADCs, peptides, CAR-T, and mRNA therapeutics. The division has supported over 1,200 successful IND submissions, conducting 10,000+ in vitro and 5,000+ in vivo studies per year through 300+ validated bioanalytical methods.

The business operates on a fee-for-service contract testing model with quote-based pricing for integrated IND-enabling and NDA-enabling packages, as well as a la carte assay services on multi-year contracts. Distribution is enterprise-direct via field sales teams and dedicated project managers engaged with pharmaceutical and biotech sponsors. The division holds first-mover regulatory positions in China, including the first CMC platform to pass FDA inspection for new chemical entities, the first GLP preclinical laboratory double-certified with OECD and NMPA, and the first GLP/GCP bioanalytical laboratory passing FDA, OECD, and NMPA inspections. As a business unit of WuXi AppTec (publicly traded on the Shanghai Stock Exchange, ticker 603259), the Laboratory Testing Division benefits from the parent group's scale and corporate infrastructure but does not have separately disclosed revenue or financials.

WuXi AppTec, Laboratory Testing Division firmographics

Firmographics
Name
WuXi AppTec, Laboratory Testing Division
Legal name
WuXi AppTec
Website
https://labtesting.wuxiapptec.com
Company type
Public
Operating status
Operating
Headcount range
51–100 employees
Short description
WuXi AppTec's Laboratory Testing Division is a global CRO providing preclinical drug development testing services—including bioanalytical, DMPK, and safety assessment—to pharmaceutical and biotechnology companies across the US, Europe, and China.
Ownership category
akta.pro rank

WuXi AppTec, Laboratory Testing Division industry classification

Industry
Product category
Preclinical Drug Development Testing Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAK
Bioanalytical & Biomarker Assays (Preclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAC
Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Preclinical testing services
  • Bioanalytical services
  • Drug metabolism pharmacokinetics
  • Safety assessment services
  • IND-enabling studies

Where WuXi AppTec, Laboratory Testing Division is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices4 records

Markets served

WuXi AppTec, Laboratory Testing Division business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Contract Preclinical Testing Services: Fee-for-service preclinical testing contracts covering DMPK, bioanalysis, safety assessment, and regulatory support for drug development programs. Services offered as integrated IND/NDA packages or individual assays

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom IND-Enabling and NDA-Enabling Packages

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

WuXi AppTec, Laboratory Testing Division product offering

Product offering

Core offering

Contract preclinical drug development testing services for pharmaceutical and biotechnology companies, covering three integrated pillars: Bioanalytical Services (small and large molecule quantification using LC-MS/MS and immunoassays), DMPK Services (in vitro ADME, in vivo PK, metabolite profiling, radiolabeled ADME), and Safety Assessment Services (general toxicology, safety pharmacology, genetic toxicology, DART, carcinogenicity). Services span the full preclinical continuum from discovery through IND and NDA submissions to FDA, EMA, and NMPA across small molecules, biologics, and emerging therapeutic modalities including PROTACs, oligonucleotides, ADCs, peptides, CAR-T, and mRNA.

Product overview

WuXi AppTec Laboratory Testing Division offers a comprehensive, fully integrated preclinical drug development platform encompassing three core service pillars: Bioanalytical Services, DMPK Services, and Safety Assessment Services. These are delivered across multiple therapeutic modality categories (Small Molecule, Large Molecule, and New Modalities including Oligonucleotides, ADCs, Peptides, Protein Degraders/PROTACs, CAR-T, and mRNA). The platform provides end-to-end capabilities from discovery through IND and NDA submission, with global operations in the U.S. and China. Services are delivered through dedicated solutions for IND-Enabling and NDA-Enabling programs, supported by advanced technology platforms including LC-MS/MS, immunoassays, and high-throughput screening systems.

Differentiator

Problem solved

Functional benefit

Products and services

  • Preclinical Drug Development Services Comprehensive preclinical drug development testing services encompassing bioanalytical, DMPK, and toxicology testing to support drug candidates from early discovery through IND and NDA submission for pharmaceutical and biotechnology companies.
  • IND-Enabling Services Preclinical studies and regulatory submission support designed to prepare drug candidates for Investigational New Drug (IND) applications to FDA, NMPA, and EMA.
  • NDA-Enabling Services GLP safety assessment and bioanalytical testing services to support New Drug Application (NDA) submissions through Phase I, II, and III clinical trials for pharmaceutical sponsors.
  • Small Molecule Solutions Integrated preclinical testing platform for small molecule therapeutics covering DMPK/ADME, bioanalysis, safety assessment, pharmacology, and CMC from discovery through NDA submission.
  • Large Molecule Solutions Preclinical development services for biologics and biotherapies including bioanalytical, DMPK, safety assessment, pharmacology, and CMC capabilities.
  • New Modalities Solutions Preclinical testing services for emerging therapeutic modalities including PROTACs, oligonucleotides, ADCs, peptides, CAR-T, and mRNA therapeutics.
  • Oligonucleotide Solutions Comprehensive testing services for oligonucleotide therapeutics covering in vitro stability, in vivo pharmacokinetics, advanced bioanalysis, and specialized safety assessments for ASOs, siRNAs, and mRNA oligonucleotides.
  • Antibody-Drug Conjugate (ADC) Solutions End-to-end preclinical testing services for antibody-drug conjugates including linker stability, payload release kinetics, tissue distribution, and specialized bioanalysis for total antibody, intact ADC, and DAR analysis.
  • Peptide Solutions Preclinical testing services for peptide therapeutics including stability assessment, permeability evaluation, tissue distribution, and specialized immunogenicity monitoring for peptides 500-5,000 Da.
  • Protein Degrader Solutions (PROTAC) Specialized testing for targeted protein degraders including PROTACs, molecular glues, and lysosome-directed approaches with capabilities for physicochemical characterization, metabolic profiling, and off-target degradation screening.
  • CAR-T Solutions Preclinical testing services for chimeric antigen receptor T-cell therapies including bioanalysis, biomarker analysis, in vitro and in vivo assays, and immunophenotyping for hematologic malignancies.
  • mRNA Solutions Preclinical testing services for mRNA therapeutics and vaccines including biodistribution studies tracking mRNA and translated proteins, delivery system characterization, and tissue-specific translation assessment.
  • Bioanalytical Services Comprehensive bioanalysis platform supporting small and large molecule programs through discovery, preclinical, and clinical phases with LC-MS/MS, immunoassays, and biomarker validation.
  • DMPK Services Drug metabolism and pharmacokinetic services including in vitro ADME, in vivo PK studies, metabolite profiling, and radiolabeled ADME studies spanning discovery through clinical phases.
  • Safety Assessment Services Comprehensive safety assessment services including general toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology (DART), and carcinogenicity testing across multiple species.

Quantifiable outcome

  • 1,200+ successful IND submissions completed
  • +3 more outcomes

Companies that use WuXi AppTec, Laboratory Testing Division

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

WuXi AppTec, Laboratory Testing Division technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

WuXi AppTec, Laboratory Testing Division partnerships and signals

Strategic signal

Scale indicators17 records

Recent moves6 records

Expansion highlights5 records

WuXi AppTec, Laboratory Testing Division competitors and assessment

Company assessment

Direct peers

  • Eurofins Scientific: Global testing services group with significant pharma clinical and preclinical testing, bioanalytical, and DMPK offerings through Eurofins Discovery and Pharma Services; comparable on testing services model and customer overlap.
  • Inotiv: Preclinical CRO specializing in safety assessment, DMPK, bioanalysis, and research models for pharma/biotech; comparable on GLP toxicology and bioanalytical service lines.
  • Frontage Laboratories: U.S./China-based CRO providing bioanalytical, DMPK, CMC, and preclinical services to pharma/biotech; directly comparable on integrated IND-enabling preclinical offerings and bilateral U.S.–China footprint.
  • Labcorp Drug Development (Fortrea): Post-spin preclinical and clinical CRO offering DMPK, bioanalytical, safety assessment, and central laboratory services to pharma/biotech sponsors; directly comparable in service portfolio and customer base.
  • Charles River Laboratories: Global CRO with a large preclinical Safety Assessment and DMPK/Bioanalysis business serving pharmaceutical and biotech clients across small molecules and biologics; directly comparable in core service lines (GLP toxicology, bioanalysis, DMPK) and end customers.
  • Pharmaron: China-headquartered CRO/CDMO offering integrated preclinical drug discovery, DMPK, bioanalytical and safety assessment services to global pharma/biotech sponsors; directly comparable in service mix, China-based scale, and customer base.
  • SGS Health Sciences: Global CRO providing preclinical and clinical bioanalytical, DMPK, and central laboratory services to pharmaceutical and biotech clients; directly comparable in GLP bioanalytical and central lab offerings.

Broad incumbents

  • ICON plc: Global CRO with preclinical laboratory services (post-PRA and early-development services acquisitions) serving pharma/biotech sponsors; overlapping in bioanalytical and central lab services with broader clinical focus.
  • IQVIA: Diversified life sciences services giant with preclinical and bioanalytical capabilities embedded in its broader R&D Solutions and laboratory services; comparable on bioanalysis/DMPK but broader in clinical and data offerings.

Regional players

  • Hangzhou Tigermed: China-headquartered clinical CRO with growing preclinical/biologics services targeting China and global pharma; adjacent comparable as a Chinese peer serving similar pharma/biotech sponsors with expanding preclinical capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

WuXi AppTec, Laboratory Testing Division social profiles

Digital presence

WuXi AppTec, Laboratory Testing Division financial estimates

Financial estimate

Revenue estimate

Valuation estimate

WuXi AppTec, Laboratory Testing Division leadership team

Management profile

Number of profiles

Profiles1 record

WuXi AppTec, Laboratory Testing Division funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

WuXi AppTec, Laboratory Testing Division M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WuXi AppTec, Laboratory Testing Division

What does WuXi AppTec, Laboratory Testing Division do?

Contract preclinical drug development testing services for pharmaceutical and biotechnology companies, covering three integrated pillars: Bioanalytical Services (small and large molecule quantification using LC-MS/MS and immunoassays), DMPK Services (in vitro ADME, in vivo PK, metabolite profiling, radiolabeled ADME), and Safety Assessment Services (general toxicology, safety pharmacology, genetic toxicology, DART, carcinogenicity). Services span the full preclinical continuum from discovery through IND and NDA submissions to FDA, EMA, and NMPA across small molecules, biologics, and emerging therapeutic modalities including PROTACs, oligonucleotides, ADCs, peptides, CAR-T, and mRNA.

Is WuXi AppTec, Laboratory Testing Division a public or private company?

WuXi AppTec, Laboratory Testing Division is a public company. It is classified as public and is currently operating.

When was WuXi AppTec, Laboratory Testing Division founded?

WuXi AppTec, Laboratory Testing Division was founded in -1. It employs 51 to 100 people.

Where is WuXi AppTec, Laboratory Testing Division based?

WuXi AppTec, Laboratory Testing Division is headquartered in Shanghai, China, in the Asia region.

How does WuXi AppTec, Laboratory Testing Division make money?

One revenue line is on record: contract Preclinical Testing Services.

Who are WuXi AppTec, Laboratory Testing Division's main competitors?

Direct peers on record are Eurofins Scientific, Inotiv, Frontage Laboratories, Labcorp Drug Development (Fortrea), Charles River Laboratories, Pharmaron and SGS Health Sciences. Broad incumbents are ICON plc and IQVIA. Hangzhou Tigermed is listed as a regional player.

Does WuXi AppTec, Laboratory Testing Division have an API?

No public API is recorded for WuXi AppTec, Laboratory Testing Division.

What industry is WuXi AppTec, Laboratory Testing Division in?

WuXi AppTec, Laboratory Testing Division's product category is Preclinical Drug Development Testing Services. Its primary akta.pro industry code is HLAGAFAC, DMPK / ADME & Bioanalysis, with a secondary code of HLAGAFAN, Nonclinical Study Management & Regulatory Writing (IND-enabling). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales